TheraRadar
← Back
Data updated: Mar 29, 2026

LEO PHARMA AS

DermatologyImmunologyOncology
Big Pharma

LEO PHARMA AS is a major pharmaceutical company focused on Dermatology, Immunology, Oncology. Key products include ADBRY.

1993
Since
9
Drugs
-
Trials
6
Approved (2yr)

Key Drugs

ADBRY
tralokinumab
Immunology
IL-13 1 indications · 2021
ANZUPGO
delgocitinib
JAK1 1 indications · 2025
ENSTILAR
betamethasone dipropionate
Immunology
Glucocorticoid receptor 1 indications · 2015

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Recent Activity

ADBRY 2025-12-17
Type 1 - New Molecular Entity
ADBRY 2025-12-12
Labeling
DOVONEX 2025-10-03
Labeling
DOVONEX 2025-10-03
Labeling
ANZUPGO 2025-07-23
Type 1 - New Molecular Entity
ADBRY 2024-06-12
Efficacy
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Dermatology 66%
2 drugs Phase 3: 17 Phase 2: 14 Phase 1: 11
Immunology 32%
2 drugs Phase 3: 6 Phase 2: 4 Phase 1: 13
Oncology 2%
0 drugs Phase 3: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Dermatology, Immunology
Eli Lilly big-pharma
Oncology, Immunology, Dermatology
COSETTE other
Dermatology, Immunology, Oncology
Novartis big-pharma
Oncology, Immunology
Merck big-pharma
Oncology, Immunology